RNAM

Avidity Biosciences, Inc.

RNAM · CIK 1599901 · Annual (10-K) · Last 6 years

Financial Trends

Revenue$19M
20202025
Net Income−$685M
20202025
Operating CF−$650M
20202025
Free Cash Flow−$664M
20202025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue——————
Gross Profit——————
R&D Expense$0.6B$0.3B$0.2B$0.2B$0.1B$0.0B
SG&A Expense——————
Operating Income$-0.7B$-0.4B$-0.2B$-0.2B$-0.1B$-0.0B
Net Income$-0.7B$-0.3B$-0.2B$-0.2B$-0.1B$-0.0B
EPS (Basic)$-4.97$-2.89$-2.91$-3.34——
EPS (Diluted)$-4.97$-2.89$-2.91$-3.34——

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$2.0B$1.6B$0.6B$0.6B$0.4B$0.3B
Current Assets$1.8B$1.5B$0.6B$0.6B$0.4B$0.3B
Cash & Equivalents$0.4B$0.2B$0.2B$0.3B$0.3B$0.3B
Total Liabilities$0.3B$0.1B$0.1B$0.1B$0.0B$0.0B
Current Liabilities$0.2B$0.1B$0.1B$0.1B$0.0B$0.0B
Stockholders' Equity$1.7B$1.4B$0.5B$0.6B$0.4B$0.3B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.7B$-0.3B$-0.1B$-0.1B$-0.1B$-0.0B
Investing Cash Flow$-0.0B$-0.9B$-0.1B$-0.2B$-0.1B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.9B$1.2B$0.1B$0.3B$0.2B$0.3B
← Companies